The DOI matches its Crossref record, with a small difference in title or year; 88 of the 88 references it cites were found in a registry or an index.
The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications Report on a Policy Conference of the European Society of Cardiology
Abstract
(for the other speakers in the sessions and the chairs of the workshops see) The Policy Conference on The Potential for QT Prolongation and Pro-arrhythmia by Non-anti-arrhythmic Drugs. Clinical and Regulatory Implications was held at the European Heart House in Sophia Antipolis, France, on the initiative of Günter Breithardt, FESC, FACC, on June 24th and 25th, 1999 after formal approval by the Board of the European Society of Cardiology (ESC). The conference was organised under the auspices of the ESC Committee for Scientific and Clinical Initiatives by Günter Breithardt and Wilhelm Haverkamp, Münster, Germany, with participation of representatives of the Working Group on Arrhythmias of the ESC, the American College of Cardiology, the American Heart Association, the World Heart Federation, the European Agency for the Evaluation of Medicinal Products, the Medicines Control Agency (UK), the Food and Drug Administration (USA), the National Heart, Lung and Blood Institute (USA), the Federal Institute for Drugs and Medical Devices (Germany), and the Medical Products Agency (Sweden).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A prolonged QT interval predisposes to the development of ventricular tachyarrhythmias such as torsade de pointes and ventricular fibrillation, which could cause syncope, cardiac arrest, or SCD (Haverkamp et al., 2000;Moss, 1999;Zareba et al., 1995).”
From 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry (2017) · cites this paper as Haverkamp et al., 2000
In the citing paper
“Identifying patients at risk of proarrhythmia can help to mitigate the proarrhythmic risk of antiarrhythmic drugs.668”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [668]
Citations
Cites
Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency
Farooqi, I. S., Jebb, S. A., Langmack, G., Lawrence, E., Cheetham, C. H., Prentice, A. M., Hughes, I. A., McCamish, M. A., & O'Rahilly, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411204 · Cited by 1,998
MiRP1 Forms IKr Potassium Channels with HERG and Is Associated with Cardiac Arrhythmia
Abbott, G. W., Sesti, F., Splawski, I., Buck, M. E., Lehmann, M. H., Timothy, K. W., Keating, M. T., & Goldstein, S. A. N. (1999) · Cell · doi:10.1016/s0092-8674(00)80728-x · Cited by 1,354
Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction
Torp-Pedersen, C., Møller, M., Bloch-Thomsen, P. E., Køber, L., Sandøe, E., Egstrup, K., Agner, E., Carlsen, J., Videbæk, J., Marchant, B., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411201 · Cited by 1,012
Female Gender as a Risk Factor for Torsades de Pointes Associated With Cardiovascular Drugs
Makkar, R. R. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03510210076031 · Cited by 971
Low Penetrance in the Long-QT Syndrome: Clinical Impact
Priori, S. G., Napolitano, C., & Schwartz, P. J. (1999) · Circulation · doi:10.1161/01.cir.99.4.529 · Cited by 804
Electrophysiological remodeling in hypertrophy and heart failure
Tomaselli, G. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00017-6 · Cited by 748
An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study)
Sagie, A., Larson, M. G., Goldberg, R. J., Bengtson, J. R., & Levy, D. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)90562-d · Cited by 715
Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current.
January, C. T., & Riddle, J. M. (1989) · Circulation Research · doi:10.1161/01.res.64.5.977 · Cited by 673
Taking the “Idio” out of “Idiosyncratic”: Predicting Torsades de Pointes
RODEN, D. M. (1998) · Pacing and Clinical Electrophysiology · doi:10.1111/j.1540-8159.1998.tb00148.x · Cited by 667
Terfenadine-Ketoconazole Interaction: Pharmacokinetic and Electrocardiographic Consequences
Honig, P. K. (1993) · JAMA · doi:10.1001/jama.1993.03500120051025 · Cited by 664
Cited by
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · Europace · doi:10.1093/europace/euw295 · Cited by 6,439
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
“2 The twelve-lead electrocardiogram as a tool to identify patients at risk of pro-arrhythmia Identifying patients at risk of pro-arrhythmia can help to mitigate the pro-arrhythmic risk of antiarrhythmic drugs.(668) In addition to the clinical characteristics mentioned above, monitoring PR, QT, and QRS durations during…”
2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castellá, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.11.033 · Cited by 1,801
REDFERN, W., CARLSSON, L., DAVIS, A., LYNCH, W., MACKENZIE, I., PALETHORPE, S., SIEGL, P., STRANG, I., SULLIVAN, A., & WALLIS, R. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00846-5 · Cited by 1,532
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezw313 · Cited by 1,403
Metadata
- Authors
- Haverkamp*, W.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-08
- Volume
- 47
- Issue
- 2
- Pages
- 219-233
- ISSN
- 0008-6363 (ISSN-L)
- OpenAlex
- W2174038367
- Cited by
- 486
- References
- 87
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 4 · 2023: 7 · 2022: 2 · 2021: 12 · 2020: 18 · 2019: 3 · 2018: 10 · 2017: 21 · 2016: 21 · 2015: 12 · 2014: 21 · 2013: 21 · 2012: 22
- FWCI
- 21.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cardiovascular Research (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac pacing and defibrillation studies
- Keywords
- QT prolongation, drug-induced arrhythmia, drug safety regulation, pharmacovigilance, adverse drug reactions, regulatory policy
- MeSH terms
- Action Potentials, Animals, Anti-Arrhythmia Agents, Anti-Bacterial Agents, Cardiology, Clinical Trials as Topic, Disease Models, Animal, Drug and Narcotic Control, Europe, Humans, Product Surveillance, Postmarketing, Research, Societies, Medical, Antipsychotic Agents, Vasodilator Agents, Potassium Channels, Torsades de Pointes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications Report on a Policy Conference of the European Society of Cardiology. https://app.cochat.ai/papers/10.1016/s0008-6363(00)00119-x
- The paper
- Haverkamp*, W. (2000). The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications Report on a Policy Conference of the European Society of Cardiology. Cardiovascular Research. https://doi.org/10.1016/s0008-6363(00)00119-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.